Sodium glucose cotransporter 2 inhibitors (SGLT-2) and glucagon-like peptide 1 receptor (GLP-1) agonists have proven benefits in the treatment of atherosclerotic cardiovascular disease (ASCVD) and are indicated for patients co-diagnosed with type 2 diabetes (T2D) and ASCVD, at high risk for ASCVD, or with heart failure (HF) irrespective of surrogate markers of diabetes control [2]. This evidence concerns the gene GLP1R and hydrops fetalis.